{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T01:40:24Z","timestamp":1758678024705,"version":"3.44.0"},"publisher-location":"Cham","reference-count":269,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031945397"},{"type":"electronic","value":"9783031945403"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-94540-3_3","type":"book-chapter","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T14:51:24Z","timestamp":1756565484000},"page":"31-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TB or Not TB: The Parallel Lives of BCG"],"prefix":"10.1007","author":[{"given":"Mayra Fernanda","family":"Mart\u00ednez-L\u00f3pez","sequence":"first","affiliation":[]},{"given":"Pedro","family":"Curto","sequence":"additional","affiliation":[]},{"given":"Palmira","family":"Barreira-Silva","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Fior","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Moura-Alves","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"issue":"12","key":"3_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/thx.2010.140996","volume":"65","author":"A Lalvani","year":"2010","unstructured":"Lalvani A, Sridhar S. BCG vaccination: 90 years on and still so much to learn. Thorax. 2010;65(12):1036\u20138.","journal-title":"Thorax"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fimmu.2017.01134","volume":"8","author":"HM Dockrell","year":"2017","unstructured":"Dockrell HM, Smith SG. What have we learnt about BCG vaccination in the last 20 years? Front Immunol. 2017;8:1134.","journal-title":"Front Immunol"},{"issue":"10","key":"3_CR3","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.vaccine.2004.09.006","volume":"23","author":"LG Stensballe","year":"2005","unstructured":"Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. 2005;23(10):1251\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"3_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3143\/geriatrics.42.34","volume":"42","author":"T Ohrui","year":"2005","unstructured":"Ohrui T, Nakayama K, Fukushima T, Chiba H, Sasaki H. Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations. Nihon Ronen Igakkai Zasshi. 2005;42(1):34\u20136.","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"2","key":"3_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med. 2018;379(2):138\u201349.","journal-title":"N Engl J Med"},{"issue":"3","key":"3_CR6","first-page":"185","volume":"43","author":"DEA Wardhana","year":"2011","unstructured":"Wardhana DEA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43(3):185\u201390.","journal-title":"Acta Med Indones"},{"issue":"1","key":"3_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","volume":"23","author":"RJW Arts","year":"2018","unstructured":"Arts RJW, Moorlag S, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23(1):89\u2013100 e5.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"3_CR8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41467-019-08659-3","volume":"10","author":"J Walk","year":"2019","unstructured":"Walk J, de Bree LCJ, Graumans W, Stoter R, van Gemert GJ, van de Vegte-Bolmer M, et al. Outcomes of controlled human malaria infection after BCG vaccination. Nat Commun. 2019;10(1):874.","journal-title":"Nat Commun"},{"issue":"9","key":"3_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","volume":"17","author":"JH van Puffelen","year":"2020","unstructured":"van Puffelen JH, Keating ST, Oosterwijk E, van der Heijden AG, Netea MG, Joosten LAB, et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol. 2020;17(9):513\u201325.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"3_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2020.08.051","volume":"183","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, Antonakos N, Kotsaki A, Dominguez-Andres J, et al. Activate: randomized clinical trial of BCG vaccination against infection in the elderly. Cell. 2020;183(2):315\u201323 e9.","journal-title":"Cell"},{"issue":"6165","key":"3_CR11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432\u20133.","journal-title":"Science"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","volume":"10","author":"P Dobosz","year":"2019","unstructured":"Dobosz P, Dzieciatkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965.","journal-title":"Front Immunol"},{"key":"3_CR13","first-page":"154","volume":"26","author":"EF McCarthy","year":"2006","unstructured":"McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154\u20138.","journal-title":"Iowa Orthop J"},{"issue":"Surg Sect","key":"3_CR14","first-page":"1","volume":"3","author":"WB Coley","year":"1910","unstructured":"Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3(Surg Sect):1\u201348.","journal-title":"Proc R Soc Med"},{"key":"3_CR15","first-page":"205","volume":"6","author":"HC Nauts","year":"1946","unstructured":"Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 1946;6:205\u201316.","journal-title":"Cancer Res"},{"key":"3_CR16","first-page":"1","volume":"276","author":"HC Nauts","year":"1953","unstructured":"Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley\u2019s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley\u2019s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl. 1953;276:1\u2013103.","journal-title":"Acta Med Scand Suppl"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1002\/eji.200737772","volume":"37 Suppl 1(Supp","author":"CA Dinarello","year":"2007","unstructured":"Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37 Suppl 1(Suppl 1):S34\u201345.","journal-title":"Eur J Immunol"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2741\/1341","volume":"9","author":"B Conti","year":"2004","unstructured":"Conti B, Tabarean I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci. 2004;9:1433\u201349.","journal-title":"Front Biosci"},{"issue":"6","key":"3_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nri3843","volume":"15","author":"SS Evans","year":"2015","unstructured":"Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15(6):335\u201349.","journal-title":"Nat Rev Immunol"},{"key":"3_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.595722","volume":"12","author":"JF Rossi","year":"2021","unstructured":"Rossi JF, Lu ZY, Massart C, Levon K. Dynamic immune\/inflammation precision medicine: the good and the bad inflammation in infection and cancer. Front Immunol. 2021;12:595722.","journal-title":"Front Immunol"},{"issue":"4","key":"3_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41435-023-00213-y","volume":"24","author":"AD Garg","year":"2023","unstructured":"Garg AD. The dynamic interface of genetics and immunity: toward future horizons in health & disease. Genes Immun. 2023;24(4):155\u20138.","journal-title":"Genes Immun"},{"issue":"4","key":"3_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/toxins12040241","volume":"12","author":"RD Carlson","year":"2020","unstructured":"Carlson RD, Flickinger JC Jr, Snook AE. Talkin\u2019 toxins: from Coley\u2019s to modern cancer immunotherapy. Toxins (Basel). 2020;12(4):241.","journal-title":"Toxins (Basel)"},{"issue":"1","key":"3_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02988567","volume":"8","author":"ZY Tang","year":"1991","unstructured":"Tang ZY, Zhou HY, Zhao G, Chai LM, Zhou M, Lu JZ, et al. Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol Tumor Pharmacother. 1991;8(1):23\u20138.","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"3_CR24","unstructured":"Kempin S, Cirrincione C, Straus D, Gee T, Arlin Z, Koziner B, et al., editors. Improved remission rate and duration in nodular non-Hodgkin lymphoma (NNHL) with the use of mixed bacterial vaccine (MBV). Proceedings of the American Association for Cancer Research; 1981: Amer Assoc Cancer Research 615 Chestnut St, 17th Floor, Philadelphia, PA."},{"issue":"5","key":"3_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000217017","volume":"14","author":"K K\u00f6lmel","year":"1991","unstructured":"K\u00f6lmel K, Vehmeyer K, G\u00f6hring E, Kuhn B, Wieding J. Treatment of advanced malignant melanoma by a pyrogenic bacterial lysate. A pilot study. Oncol Res Treat. 1991;14(5):411\u20137.","journal-title":"Oncol Res Treat"},{"issue":"19","key":"3_CR26","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-12-1116","volume":"18","author":"J Karbach","year":"2012","unstructured":"Karbach J, Neumann A, Brand K, Wahle C, Siegel E, Maeurer M, et al. Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res. 2012;18(19):5449\u201359.","journal-title":"Clin Cancer Res"},{"key":"3_CR27","volume-title":"Zebrafish avatars as a model for immunotherapy response in bladder cancer [PhD]","author":"MFM L\u00f3pez","year":"2022","unstructured":"L\u00f3pez MFM. Zebrafish avatars as a model for immunotherapy response in bladder cancer [PhD]. Lisbon, Portugal: Universidade Nova de Lisboa; 2022."},{"issue":"Suppl 5","key":"3_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/184291a0","volume":"184","author":"LJ Old","year":"1959","unstructured":"Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959;184(Suppl 5):291\u20132.","journal-title":"Nature"},{"issue":"3980","key":"3_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.172.3980.271","volume":"172","author":"B Zbar","year":"1971","unstructured":"Zbar B, Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science. 1971;172(3980):271\u20133.","journal-title":"Science"},{"issue":"6","key":"3_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/0090-4295(73)90328-2","volume":"2","author":"C Merrin","year":"1973","unstructured":"Merrin C, Han T, Klein E, Murphy GP. Immunotherapy of prostatic cancer with Bacillus Calmette-Guerin and purified protein derivative. Preliminary results. Urology. 1973;2(6):651\u20134.","journal-title":"Urology"},{"key":"3_CR31","first-page":"351","volume":"49","author":"MR Robinson","year":"1978","unstructured":"Robinson MR, Rigby CC, Pugh RC, Dumonde DC. Prostate carcinoma: intratumor BCG immunotherapy. Natl Cancer Inst Monogr. 1978;49:351\u20133.","journal-title":"Natl Cancer Inst Monogr"},{"issue":"6","key":"3_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/0090-4295(79)90523-5","volume":"14","author":"P Guinan","year":"1979","unstructured":"Guinan P, Crispen R, Baumgartner G, Rao R, Totonchi E, Ablin R, et al. Adjuvant immunotherapy with Bacillus Calmette-Guerin in prostatic cancer. Urology. 1979;14(6):561\u20135.","journal-title":"Urology"},{"issue":"4","key":"3_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","volume":"180","author":"DL Morton","year":"1974","unstructured":"Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180(4):635\u201343.","journal-title":"Ann Surg"},{"issue":"4","key":"3_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1097-0142(19850215)55:4<707::AID-CNCR2820550406>3.0.CO;2-5","volume":"55","author":"JM Sterchi","year":"1985","unstructured":"Sterchi JM, Wells HB, Case LD, Spurr CL, White DR, Richards F, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report. Cancer. 1985;55(4):707\u201312.","journal-title":"Cancer"},{"issue":"7","key":"3_CR35","first-page":"744","volume":"131","author":"AH Paterson","year":"1984","unstructured":"Paterson AH, Willans DJ, Jerry LM, Hanson J, McPherson TA. Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J. 1984;131(7):744\u20138.","journal-title":"Can Med Assoc J"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/978-3-642-81332-0_58","volume":"68","author":"AH Paterson","year":"1978","unstructured":"Paterson AH, Willans D, Jerry LM, McPherson TA. Malignant melanoma (stage 1): a clinical trial of adjuvant BCG immunotherapy. Recent Results Cancer Res. 1978;68:387\u201392.","journal-title":"Recent Results Cancer Res"},{"key":"3_CR37","unstructured":"National Comprehensive Cancer Network [Internet]. 2024 [Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492."},{"issue":"1","key":"3_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02468640","volume":"10","author":"EC Holmes","year":"1980","unstructured":"Holmes EC. BCG immunotherapy of lung cancer. Jpn J Surg. 1980;10(1):1\u20136.","journal-title":"Jpn J Surg"},{"issue":"5","key":"3_CR39","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/1097-0142(197511)36:5<1662::AID-CNCR2820360520>3.0.CO;2-6","volume":"36","author":"JB deKernion","year":"1975","unstructured":"deKernion JB, Golub SH, Gupta RK, Silverstein M, Morton DL. Successful transurethral intralesional BCG therapy of a bladder melanoma. Cancer. 1975;36(5):1662\u20137.","journal-title":"Cancer"},{"issue":"6","key":"3_CR40","first-page":"423","volume":"12","author":"SD Bloomberg","year":"1975","unstructured":"Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD. The effects of BCG on the dog bladder. Investig Urol. 1975;12(6):423\u20137.","journal-title":"Investig Urol"},{"issue":"2","key":"3_CR41","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u20133.","journal-title":"J Urol"},{"issue":"2","key":"3_CR42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/jso.2930260206","volume":"26","author":"M Eriguchi","year":"1984","unstructured":"Eriguchi M, Fujii G. Oral administration of BCG as a local immunotherapy of gastrointestinal cancer. J Surg Oncol. 1984;26(2):100\u20136.","journal-title":"J Surg Oncol"},{"issue":"1","key":"3_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.2000.18.1.148","volume":"18","author":"JE Harris","year":"2000","unstructured":"Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB 3rd, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18(1):148\u201357.","journal-title":"J Clin Oncol"},{"issue":"17\u201318","key":"3_CR44","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.vaccine.2005.01.015","volume":"23","author":"CA Uyl-de Groot","year":"2005","unstructured":"Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, Verboom P, Groot MT, Bonsel GJ, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005;23(17\u201318):2379\u201387.","journal-title":"Vaccine"},{"issue":"2","key":"3_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2141.1977.tb00583.x","volume":"35","author":"JA Whittaker","year":"1977","unstructured":"Whittaker JA, Slater AJ. The immunotherapy of acute myelogenous leukaemia using intravenous BCG. Br J Haematol. 1977;35(2):263\u201373.","journal-title":"Br J Haematol"},{"issue":"5","key":"3_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bjc.1973.162","volume":"28","author":"RL Powles","year":"1973","unstructured":"Powles RL, Crowther D, Bateman CJ, Beard ME, McElwain TJ, Russell J, et al. Immunotherapy for acute myelogenous leukaemia. Br J Cancer. 1973;28(5):365\u201376.","journal-title":"Br J Cancer"},{"issue":"5846","key":"3_CR47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/bmj.1.5846.131","volume":"1","author":"D Crowther","year":"1973","unstructured":"Crowther D, Powles RL, Bateman CJ, Beard ME, Gauci CL, Wrigley PF, et al. Management of adult acute myelogenous leukaemia. Br Med J. 1973;1(5846):131\u20137.","journal-title":"Br Med J"},{"issue":"5","key":"3_CR48","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/bjc.1979.254","volume":"40","author":"GP Summerfield","year":"1979","unstructured":"Summerfield GP, Gibbs TJ, Bellingham AJ. Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia. Br J Cancer. 1979;40(5):736\u201342.","journal-title":"Br J Cancer"},{"key":"3_CR49","doi-asserted-by":"crossref","unstructured":"Heyn RM, Joo P, Karon M, Nesbit M, Shore N, Breslow N, et al. BCG in the treatment of acute lymphocytic leukemia. 1975. p. 431. American Society of Hematology - Blood, 2021 L St. NW, Suite 900, Washington DC 20036-4929, USA.","DOI":"10.1182\/blood.V46.3.431.bloodjournal463431"},{"key":"3_CR50","unstructured":"World Cancer Research Fund International [Internet]. 2022 [Available from: https:\/\/www.wcrf.org\/cancer-trends\/bladder-cancer-statistics\/."},{"issue":"7679","key":"3_CR51","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1038\/551S34a","volume":"551","author":"C Berdik","year":"2017","unstructured":"Berdik C. Unlocking bladder cancer. Nature. 2017;551(7679):S34\u2013S5.","journal-title":"Nature"},{"issue":"19","key":"3_CR52","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324(19):1980\u201391.","journal-title":"JAMA"},{"issue":"1","key":"3_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","volume":"16","author":"B Jordan","year":"2019","unstructured":"Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019;16(1):23\u201334.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"3_CR55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"1","key":"3_CR56","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104.","journal-title":"Eur Urol"},{"key":"3_CR57","volume-title":"Biochemistry, Glycosaminoglycans","author":"J Casale","year":"2024","unstructured":"Casale J, Crane JS. Biochemistry, Glycosaminoglycans. Treasure Island: StatPearls; 2024."},{"issue":"3","key":"3_CR58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-2007-1001917","volume":"20","author":"DH Schamhart","year":"1994","unstructured":"Schamhart DH, De Boer EC, Vleeming R, Kurth KH. Theoretical and experimental evidence on the use of glycosaminoglycans in BCG-mediated immunotherapy of superficial bladder cancer. Semin Thromb Hemost. 1994;20(3):301\u20139.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"3_CR59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s13213-013-0758-y","volume":"64","author":"C Ayala-Torres","year":"2014","unstructured":"Ayala-Torres C, Hern\u00e1ndez N, Galeano A, Novoa-Aponte L, Soto C-Y. Zeta potential as a measure of the surface charge of mycobacterial cells. Ann Microbiol. 2014;64(3):1189\u201395.","journal-title":"Ann Microbiol"},{"issue":"7","key":"3_CR60","first-page":"1762","volume":"47","author":"TL Ratliff","year":"1987","unstructured":"Ratliff TL, Palmer JO, McGarr JA, Brown EJ. Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res. 1987;47(7):1762\u20136.","journal-title":"Cancer Res"},{"issue":"12","key":"3_CR61","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1128\/iai.56.12.3046-3051.1988","volume":"56","author":"C Abou-Zeid","year":"1988","unstructured":"Abou-Zeid C, Ratliff TL, Wiker HG, Harboe M, Bennedsen J, Rook GA. Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun. 1988;56(12):3046\u201351.","journal-title":"Infect Immun"},{"issue":"1","key":"3_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","volume":"86","author":"W Zhao","year":"2000","unstructured":"Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL. Role of a Bacillus Calmette-Gu\u00e9rin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer. 2000;86(1):83\u20138.","journal-title":"Int J Cancer"},{"issue":"3","key":"3_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00299721","volume":"20","author":"JS Teppema","year":"1992","unstructured":"Teppema JS, de Boer EC, Steerenberg PA, van der Meijden AP. Morphological aspects of the interaction of Bacillus Calmette-Guerin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol Res. 1992;20(3):219\u201328.","journal-title":"Urol Res"},{"issue":"4","key":"3_CR64","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","volume":"181","author":"A Bisiaux","year":"2009","unstructured":"Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J Urol. 2009;181(4):1571\u201380.","journal-title":"J Urol"},{"issue":"1","key":"3_CR65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"LR Kavoussi","year":"1990","unstructured":"Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest. 1990;85(1):62\u20137.","journal-title":"J Clin Invest"},{"issue":"6","key":"3_CR66","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.urology.2012.09.065","volume":"81","author":"MJ Lipsky","year":"2013","unstructured":"Lipsky MJ, Badalato GM, Motamedinia P, Hruby GW, McKiernan JM. The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer. Urology. 2013;81(6):1273\u20138.","journal-title":"Urology"},{"issue":"137","key":"3_CR67","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot C, Rentsch CA, Gsponer JR, Birkhauser FD, Jusforgues-Saklani H, Lemaitre F, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012;4(137):137ra72.","journal-title":"Sci Transl Med"},{"issue":"5","key":"3_CR68","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0022-5347(05)66410-5","volume":"165","author":"C Durek","year":"2001","unstructured":"Durek C, Richter E, Basteck A, Rusch-Gerdes S, Gerdes J, Jocham D, et al. The fate of Bacillus Calmette-Guerin after intravesical instillation. J Urol. 2001;165(5):1765\u20138.","journal-title":"J Urol"},{"issue":"Suppl 3","key":"3_CR69","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1086\/314066","volume":"31","author":"S Prescott","year":"2000","unstructured":"Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms. Clin Infect Dis. 2000;31(Suppl 3):S91\u20133.","journal-title":"Clin Infect Dis"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2172-8-6","volume":"8","author":"MR Saban","year":"2007","unstructured":"Saban MR, Simpson C, Davis C, Wallis G, Knowlton N, Frank MB, et al. Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG). BMC Immunol. 2007;8:6.","journal-title":"BMC Immunol"},{"issue":"3","key":"3_CR71","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-12-1882","volume":"73","author":"G Redelman-Sidi","year":"2013","unstructured":"Redelman-Sidi G, Iyer G, Solit DB, Glickman MS. Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer Res. 2013;73(3):1156\u201367.","journal-title":"Cancer Res"},{"issue":"3","key":"3_CR72","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1464-410X.1989.tb05187.x","volume":"63","author":"S Prescott","year":"1989","unstructured":"Prescott S, James K, Busuttil A, Hargreave TB, Chisholm GD, Smyth JF. HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol. 1989;63(3):264\u20139.","journal-title":"Br J Urol"},{"issue":"10","key":"3_CR73","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615\u201325.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"3_CR74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.urolonc.2007.11.031","volume":"26","author":"MP Simons","year":"2008","unstructured":"Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol. 2008;26(4):341\u20135.","journal-title":"Urol Oncol"},{"issue":"10","key":"3_CR75","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"AT Ludwig","year":"2004","unstructured":"Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 2004;64(10):3386\u201390.","journal-title":"Cancer Res"},{"issue":"1","key":"3_CR76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","volume":"21","author":"Y Luo","year":"2003","unstructured":"Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine. 2003;21(1):17\u201326.","journal-title":"Cytokine"},{"issue":"6","key":"3_CR77","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/mi.2013.72","volume":"6","author":"MA Ingersoll","year":"2013","unstructured":"Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol. 2013;6(6):1041\u201353.","journal-title":"Mucosal Immunol"},{"key":"3_CR78","volume-title":"Granuloma","author":"O Williams","year":"2024","unstructured":"Williams O, Fatima S. Granuloma. Treasure Island: StatPearls; 2024."},{"issue":"3","key":"3_CR79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/mi.2011.14","volume":"4","author":"JL Flynn","year":"2011","unstructured":"Flynn JL, Chan J, Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol. 2011;4(3):271\u20138.","journal-title":"Mucosal Immunol"},{"issue":"5","key":"3_CR80","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.cell.2016.09.054","volume":"167","author":"L Herrtwich","year":"2016","unstructured":"Herrtwich L, Nanda I, Evangelou K, Nikolova T, Horn V, Sagar, et al. DNA damage signaling instructs polyploid macrophage fate in granulomas. Cell. 2016;167(5):1264\u201380 e18.","journal-title":"Cell"},{"issue":"4","key":"3_CR81","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/jclinpath-2016-203868","volume":"70","author":"RS Dagaonkar","year":"2017","unstructured":"Dagaonkar RS, Choong CV, Asmat AB, Ahmed DB, Chopra A, Lim AY, et al. Significance of coexistent granulomatous inflammation and lung cancer. J Clin Pathol. 2017;70(4):337\u201341.","journal-title":"J Clin Pathol"},{"issue":"5b","key":"3_CR82","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1111\/bju.12334","volume":"113","author":"S Jallad","year":"2014","unstructured":"Jallad S, Goubet S, Symes A, Larner T, Thomas P. Prognostic value of inflammation or granuloma after intravesival BCG in non-muscle-invasive bladder cancer. BJU Int. 2014;113(5b):E22\u20137.","journal-title":"BJU Int"},{"issue":"4","key":"3_CR83","doi-asserted-by":"publisher","first-page":"00061","DOI":"10.1183\/23120541.00061-2020","volume":"6","author":"M Murthi","year":"2020","unstructured":"Murthi M, Yoshioka K, Cho JH, Arias S, Danna E, Zaw M, et al. Presence of concurrent sarcoid-like granulomas indicates better survival in cancer patients: a retrospective cohort study. ERJ Open Res. 2020;6(4):00061.","journal-title":"ERJ Open Res"},{"key":"3_CR84","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1146\/annurev-immunol-032712-100022","volume":"36","author":"AJ Pagan","year":"2018","unstructured":"Pagan AJ, Ramakrishnan L. The formation and function of granulomas. Annu Rev Immunol. 2018;36:639\u201365.","journal-title":"Annu Rev Immunol"},{"key":"3_CR85","volume":"2010","author":"Y Luo","year":"2010","unstructured":"Luo Y, Knudson MJ. Mycobacterium bovis Bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol. 2010;2010:357591.","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"3_CR86","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/bjc.1995.155","volume":"71","author":"K Pryor","year":"1995","unstructured":"Pryor K, Goddard J, Goldstein D, Stricker P, Russell P, Golovsky D, et al. Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer. 1995;71(4):801\u20137.","journal-title":"Br J Cancer"},{"issue":"8","key":"3_CR87","doi-asserted-by":"publisher","first-page":"dmm050693","DOI":"10.1242\/dmm.050693","volume":"17","author":"MF Martinez-Lopez","year":"2024","unstructured":"Martinez-Lopez MF, de Almeida CR, Fontes M, Mendes RV, Kaufmann SHE, Fior R. Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy. Dis Model Mech. 2024;17(8):dmm050693.","journal-title":"Dis Model Mech"},{"issue":"10","key":"3_CR88","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-03-1327","volume":"106","author":"TJ Kemp","year":"2005","unstructured":"Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, et al. Neutrophil stimulation with Mycobacterium bovis Bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL\/Apo-2L. Blood. 2005;106(10):3474\u201382.","journal-title":"Blood"},{"issue":"16","key":"3_CR89","doi-asserted-by":"publisher","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","volume":"66","author":"H Suttmann","year":"2006","unstructured":"Suttmann H, Riemensberger J, Bentien G, Schmaltz D, Stockle M, Jocham D, et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006;66(16):8250\u20137.","journal-title":"Cancer Res"},{"issue":"53","key":"3_CR90","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003;22(53):8628\u201333.","journal-title":"Oncogene"},{"issue":"3","key":"3_CR91","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150(3):1018\u201323.","journal-title":"J Urol"},{"issue":"4","key":"3_CR92","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1074-7613(03)00264-4","volume":"19","author":"R Mocikat","year":"2003","unstructured":"Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity. 2003;19(4):561\u20139.","journal-title":"Immunity"},{"key":"3_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622995","volume":"12","author":"G Esteso","year":"2021","unstructured":"Esteso G, Aguilo N, Julian E, Ashiru O, Ho MM, Martin C, et al. Natural killer anti-tumor activity can be achieved by in vitro incubation with heat-killed BCG. Front Immunol. 2021;12:622995.","journal-title":"Front Immunol"},{"issue":"1","key":"3_CR94","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/0090-1229(86)90055-3","volume":"41","author":"TL Ratliff","year":"1986","unstructured":"Ratliff TL, Shapiro A, Catalona WJ. Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. Clin Immunol Immunopathol. 1986;41(1):108\u201315.","journal-title":"Clin Immunol Immunopathol"},{"key":"3_CR95","unstructured":"Center for Disease Control and Prevention [Internet]. 2020 [Available from: https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/testing\/Tuberculin_Skin_Testing_Information_for_Health_Care_Providers.pdf."},{"issue":"2","key":"3_CR96","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0022-5347(17)45605-9","volume":"135","author":"DR Kelley","year":"1986","unstructured":"Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM, et al. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical Bacillus Calmette-Guerin. J Urol. 1986;135(2):268\u201371.","journal-title":"J Urol"},{"issue":"3","key":"3_CR97","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer \u2013 a current perspective. Nat Rev Urol. 2014;11(3):153\u201362.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"3_CR98","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.chom.2020.05.014","volume":"28","author":"B Cirovic","year":"2020","unstructured":"Cirovic B, de Bree LCJ, Groh L, Blok BA, Chan J, van der Velden W, et al. BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment. Cell Host Microbe. 2020;28(2):322\u201334 e5.","journal-title":"Cell Host Microbe"},{"issue":"10","key":"3_CR99","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","volume":"18","author":"N Lobo","year":"2021","unstructured":"Lobo N, Brooks NA, Zlotta AR, Cirillo JD, Boorjian S, Black PC, et al. 100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19. Nat Rev Urol. 2021;18(10):611\u201322.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"3_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108387","volume":"33","author":"S Moorlag","year":"2020","unstructured":"Moorlag S, Rodriguez-Rosales YA, Gillard J, Fanucchi S, Theunissen K, Novakovic B, et al. BCG vaccination induces long-term functional reprogramming of human neutrophils. Cell Rep. 2020;33(7):108387.","journal-title":"Cell Rep"},{"key":"3_CR101","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clim.2019.02.005","volume":"201","author":"K Liu","year":"2019","unstructured":"Liu K, Sun E, Lei M, Li L, Gao J, Nian X, et al. BCG-induced formation of neutrophil extracellular traps play an important role in bladder cancer treatment. Clin Immunol. 2019;201:4\u201314.","journal-title":"Clin Immunol"},{"issue":"3","key":"3_CR102","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596\u2013600.","journal-title":"J Urol"},{"issue":"3","key":"3_CR103","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","volume":"78","author":"R Li","year":"2020","unstructured":"Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, et al. Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette-Guerin. Eur Urol. 2020;78(3):387\u201399.","journal-title":"Eur Urol"},{"issue":"1","key":"3_CR104","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69\u201376.","journal-title":"Eur Urol"},{"key":"3_CR105","doi-asserted-by":"publisher","first-page":"1327053","DOI":"10.3389\/fnins.2023.1327053","volume":"17","author":"G Bourlotos","year":"2023","unstructured":"Bourlotos G, Baigent W, Hong M, Plagakis S, Grundy L. BCG induced lower urinary tract symptoms during treatment for NMIBC-mechanisms and management strategies. Front Neurosci. 2023;17:1327053.","journal-title":"Front Neurosci"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"6230409","DOI":"10.1155\/2019\/6230409","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu Y, Lu J, Huang Y, Ma L. Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Guerin for bladder cancer. J Oncol. 2019;2019:6230409.","journal-title":"J Oncol"},{"issue":"21","key":"3_CR107","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.1002\/cam4.4278","volume":"10","author":"K Sun","year":"2021","unstructured":"Sun K, Wang D, Wu G, Ma J, Wang T, Wu J, et al. Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors. Cancer Med. 2021;10(21):7534\u201341.","journal-title":"Cancer Med"},{"issue":"2","key":"3_CR108","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0022-5347(17)45606-0","volume":"135","author":"DL Lamm","year":"1986","unstructured":"Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of Bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol. 1986;135(2):272\u20134.","journal-title":"J Urol"},{"issue":"9","key":"3_CR109","volume":"10","author":"AT Guven","year":"2023","unstructured":"Guven AT, Demiroglu YZ, Kocer NE. Systemic Bacillus Calmette-Guerin (BCG) infection and accompanying warm autoimmune haemolytic anaemia following intravesical BCG immunotherapy. Eur J Case Rep Intern Med. 2023;10(9):004009.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"14","key":"3_CR110","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/jcm13144112","volume":"13","author":"R Passarelli","year":"2024","unstructured":"Passarelli R, Packiam VT. Contemporary treatment of NMIBC-is it time to move on from BCG? J Clin Med. 2024;13(14):4112.","journal-title":"J Clin Med"},{"issue":"2","key":"3_CR111","first-page":"43","volume":"22","author":"RS Matulewicz","year":"2020","unstructured":"Matulewicz RS, Steinberg GD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol. 2020;22(2):43\u201351.","journal-title":"Rev Urol"},{"issue":"4","key":"3_CR112","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"W Oosterlinck","year":"1993","unstructured":"Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993;149(4):749\u201352.","journal-title":"J Urol"},{"issue":"6","key":"3_CR113","first-page":"CD009294","volume":"6","author":"MA Han","year":"2021","unstructured":"Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021;6(6):CD009294.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"3_CR114","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","volume":"36","author":"MD Shelley","year":"2010","unstructured":"Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev. 2010;36(3):195\u2013205.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3_CR115","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","volume":"166","author":"MA O'Donnell","year":"2001","unstructured":"O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose Bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom Bacillus Calmette-Guerin alone previously failed. J Urol. 2001;166(4):1300\u20134. discussion 4-5.","journal-title":"J Urol"},{"issue":"11","key":"3_CR116","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"3_CR117","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","volume":"170","author":"SM Di Stasi","year":"2003","unstructured":"Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170(3):777\u201382.","journal-title":"J Urol"},{"issue":"1","key":"3_CR118","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan WS, Panchal A, Buckley L, Devall AJ, Loubiere LS, Pope AM, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Guerin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Guerin therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63\u201371.","journal-title":"Eur Urol"},{"issue":"6","key":"3_CR119","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046\u201352.","journal-title":"Eur Urol"},{"issue":"2","key":"3_CR120","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/ijms25021023","volume":"25","author":"N Alvarez","year":"2024","unstructured":"Alvarez N, Sevilla A. Current advances in photodynamic therapy (PDT) and the future potential of PDT-combinatorial cancer therapies. Int J Mol Sci. 2024;25(2):1023.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3_CR121","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1172\/JCI24617","volume":"115","author":"L Grode","year":"2005","unstructured":"Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest. 2005;115(9):2472\u20139.","journal-title":"J Clin Invest"},{"issue":"2","key":"3_CR122","doi-asserted-by":"publisher","first-page":"e00439-16","DOI":"10.1128\/CVI.00439-16","volume":"24","author":"AG Loxton","year":"2017","unstructured":"Loxton AG, Knaul JK, Grode L, Gutschmidt A, Meller C, Eisele B, et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol. 2017;24(2):e00439-16.","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"3_CR123","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","volume":"31","author":"L Grode","year":"2013","unstructured":"Grode L, Ganoza CA, Brohm C, Weiner J 3rd, Eisele B, Kaufmann SH. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 2013;31(9):1340\u20138.","journal-title":"Vaccine"},{"issue":"2","key":"3_CR124","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.euo.2021.12.006","volume":"5","author":"CA Rentsch","year":"2022","unstructured":"Rentsch CA, Thalmann GN, Lucca I, Kwiatkowski M, Wirth GJ, Strebel RT, et al. A phase 1\/2 single-arm clinical trial of recombinant Bacillus Calmette-Guerin (BCG) VPM1002BC immunotherapy in non-muscle-invasive bladder cancer recurrence after conventional BCG therapy: SAKK 06\/14. Eur Urol Oncol. 2022;5(2):195\u2013202.","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"3_CR125","doi-asserted-by":"publisher","first-page":"e148291","DOI":"10.1172\/JCI148291","volume":"131","author":"AK Singh","year":"2021","unstructured":"Singh AK, Netea MG, Bishai WR. BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases. J Clin Invest. 2021;131(11):e148291.","journal-title":"J Clin Invest"},{"key":"3_CR126","first-page":"57","volume":"36","author":"N Fritschi","year":"2020","unstructured":"Fritschi N, Curtis N, Ritz N. Bacille Calmette Guerin (BCG) and new TB vaccines: specific, cross-mycobacterial and off-target effects. Paediatr Respir Rev. 2020;36:57\u201364.","journal-title":"Paediatr Respir Rev"},{"issue":"12","key":"3_CR127","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","volume":"25","author":"S Moorlag","year":"2019","unstructured":"Moorlag S, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"3_CR128","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(21)00403-5","volume":"22","author":"C Lange","year":"2022","unstructured":"Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG, et al. 100 years of Mycobacterium bovis bacille Calmette-Guerin. Lancet Infect Dis. 2022;22(1):e2\u2013e12.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"3_CR129","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/infdis\/jir240","volume":"204","author":"P Aaby","year":"2011","unstructured":"Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204(2):245\u201352.","journal-title":"J Infect Dis"},{"issue":"3","key":"3_CR130","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/INF.0b013e3182458289","volume":"31","author":"S Biering-Sorensen","year":"2012","unstructured":"Biering-Sorensen S, Aaby P, Napirna BM, Roth A, Ravn H, Rodrigues A, et al. Small randomized trial among low-birth-weight children receiving Bacillus Calmette-Guerin vaccination at first health center contact. Pediatr Infect Dis J. 2012;31(3):306\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"3_CR131","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/cid\/cix525","volume":"65","author":"S Biering-Sorensen","year":"2017","unstructured":"Biering-Sorensen S, Aaby P, Lund N, Monteiro I, Jensen KJ, Eriksen HB, et al. Early BCG-Denmark and neonatal mortality among infants weighing <2500 g: a randomized controlled trial. Clin Infect Dis. 2017;65(7):1183\u201390.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3_CR132","first-page":"24","volume":"30","author":"C Lombardi","year":"1996","unstructured":"Lombardi C, Pedrazzani ES, Pedrazzani JC, Filho PF, Zicker F. Protective efficacy of BCG against leprosy in Sao Paulo. Bull Pan Am Health Organ. 1996;30(1):24\u201330.","journal-title":"Bull Pan Am Health Organ"},{"issue":"8794","key":"3_CR133","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/0140-6736(92)90794-4","volume":"339","author":"JM Ponnighaus","year":"1992","unstructured":"Ponnighaus JM, Fine PE, Sterne JA, Wilson RJ, Msosa E, Gruer PJ, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet. 1992;339(8794):636\u20139.","journal-title":"Lancet"},{"issue":"8505","key":"3_CR134","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(86)90367-3","volume":"2","author":"PE Fine","year":"1986","unstructured":"Fine PE, Ponnighaus JM, Maine N, Clarkson JA, Bliss L. Protective efficacy of BCG against leprosy in Northern Malawi. Lancet. 1986;2(8505):499\u2013502.","journal-title":"Lancet"},{"issue":"2","key":"3_CR135","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1017\/S002217240006945X","volume":"87","author":"SJ Stanley","year":"1981","unstructured":"Stanley SJ, Howland C, Stone MM, Sutherland I. BCG vaccination of children against leprosy in Uganda: final results. J Hyg (Lond). 1981;87(2):233\u201348.","journal-title":"J Hyg (Lond)"},{"issue":"3","key":"3_CR136","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1473-3099(06)70412-1","volume":"6","author":"MS Setia","year":"2006","unstructured":"Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis. 2006;6(3):162\u201370.","journal-title":"Lancet Infect Dis"},{"key":"3_CR137","doi-asserted-by":"crossref","unstructured":"BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet. 1969;1(7586):111\u20135.","DOI":"10.1016\/S0140-6736(69)91133-7"},{"issue":"5\u20136","key":"3_CR138","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/0035-9203(76)90128-0","volume":"70","author":"PG Smith","year":"1976","unstructured":"Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg. 1976;70(5\u20136):449\u201357.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"3_CR139","doi-asserted-by":"publisher","first-page":"768","DOI":"10.4269\/ajtmh.2006.75.768","volume":"75","author":"F Nackers","year":"2006","unstructured":"Nackers F, Dramaix M, Johnson RC, Zinsou C, Robert A, DE Biurrun Bakedano E, et al. BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg. 2006;75(4):768\u201374.","journal-title":"Am J Trop Med Hyg."},{"issue":"1","key":"3_CR140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003457","volume":"9","author":"RO Phillips","year":"2015","unstructured":"Phillips RO, Phanzu DM, Beissner M, Badziklou K, Luzolo EK, Sarfo FS, et al. Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl Trop Dis. 2015;9(1):e3457.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"3_CR141","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.vaccine.2020.11.045","volume":"39","author":"LF Pittet","year":"2021","unstructured":"Pittet LF, Tebruegge M, Dutta B, Donath S, Messina N, Casalaz D, et al. Mycobacterium ulcerans-specific immune response after immunisation with Bacillus Calmette-Guerin (BCG) vaccine. Vaccine. 2021;39(4):652\u20137.","journal-title":"Vaccine"},{"issue":"2","key":"3_CR142","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/microorganisms8020212","volume":"8","author":"CT Dow","year":"2020","unstructured":"Dow CT. Proposing BCG vaccination for Mycobacterium avium ss. paratuberculosis (MAP) associated autoimmune diseases. Microorganisms. 2020;8(2):212.","journal-title":"Microorganisms"},{"issue":"10","key":"3_CR143","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1097\/INF.0000000000001977","volume":"37","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Piau C, Lanotte P, Carricajo A, Guillouzouic A, Peuchant O, et al. Emergence of nontuberculous mycobacterial lymphadenitis in children after the discontinuation of mandatory Bacillus Calmette and GuErin immunization in France. Pediatr Infect Dis J. 2018;37(10):e257\u2013e60.","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"3_CR144","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/cid\/ciy241","volume":"67","author":"A Kontturi","year":"2018","unstructured":"Kontturi A, Soini H, Ollgren J, Salo E. Increase in childhood nontuberculous mycobacterial infections after Bacille Calmette-Guerin coverage drop: a nationwide, population-based retrospective study, Finland, 1995-2016. Clin Infect Dis. 2018;67(8):1256\u201361.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3_CR145","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0962-8479(05)80028-0","volume":"76","author":"V Romanus","year":"1995","unstructured":"Romanus V, Hallander HO, Wahlen P, Olinder-Nielsen AM, Magnusson PH, Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis. 1995;76(4):300\u201310.","journal-title":"Tuber Lung Dis"},{"issue":"5","key":"3_CR146","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/0962-8479(94)90080-9","volume":"75","author":"L Trnka","year":"1994","unstructured":"Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination. 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuber Lung Dis. 1994;75(5):348\u201352.","journal-title":"Tuber Lung Dis"},{"issue":"5","key":"3_CR147","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/infdis\/jiy207","volume":"218","author":"P Zimmermann","year":"2018","unstructured":"Zimmermann P, Finn A, Curtis N. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis. J Infect Dis. 2018;218(5):679\u201387.","journal-title":"J Infect Dis"},{"issue":"5","key":"3_CR148","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.129.5.973","volume":"129","author":"GB Mackaness","year":"1969","unstructured":"Mackaness GB. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med. 1969;129(5):973\u201392.","journal-title":"J Exp Med"},{"issue":"1","key":"3_CR149","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1084\/jem.120.1.105","volume":"120","author":"GB Mackaness","year":"1964","unstructured":"Mackaness GB. The immunological basis of acquired cellular resistance. J Exp Med. 1964;120(1):105\u201320.","journal-title":"J Exp Med"},{"issue":"14","key":"3_CR150","first-page":"775","volume":"101","author":"EJ Ruitenberg","year":"1976","unstructured":"Ruitenberg EJ, Steerenberg PA. Stimulation of the non-specific resistance by Corynebacterium parvum and Bacillus Calmette Guerin. Tijdschr Diergeneeskd. 1976;101(14):775\u20138.","journal-title":"Tijdschr Diergeneeskd"},{"issue":"5","key":"3_CR151","first-page":"265","volume":"84B","author":"A Jespersen","year":"1976","unstructured":"Jespersen A. Acquired resistance of BCG-vaccinated red mice to infection with Listeria monocytogenes. Acta Pathol Microbiol Scand B. 1976;84B(5):265\u201372.","journal-title":"Acta Pathol Microbiol Scand B"},{"issue":"4","key":"3_CR152","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jlb.35.4.385","volume":"35","author":"CA Nacy","year":"1984","unstructured":"Nacy CA, Meltzer MS. Macrophages in resistance to rickettsial infections: protection against lethal Rickettsia tsutsugamushi infections by treatment of mice with macrophage-activating agents. J Leukoc Biol. 1984;35(4):385\u201396.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"3_CR153","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1365-3083.1992.tb03132.x","volume":"36","author":"JW van\u2019t Wout","year":"1992","unstructured":"van\u2019t Wout JW, Poell R, van Furth R. The role of BCG\/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol. 1992;36(5):713\u20139.","journal-title":"Scand J Immunol"},{"issue":"43","key":"3_CR154","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.1202870109","volume":"109","author":"J Kleinnijenhuis","year":"2012","unstructured":"Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA. 2012;109(43):17537\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"3_CR155","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clim.2014.10.005","volume":"155","author":"J Kleinnijenhuis","year":"2014","unstructured":"Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, et al. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol. 2014;155(2):213\u20139.","journal-title":"Clin Immunol"},{"issue":"4","key":"3_CR156","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.4049\/jimmunol.114.4.1424","volume":"114","author":"L Ortiz-Ortiz","year":"1975","unstructured":"Ortiz-Ortiz L, Gonzalez-Mendoza A, Lamoyi E. A vaccination procedure against Trypanosoma cruzi infection in mice by nonspecific immunization. J Immunol. 1975;114(4):1424\u20135.","journal-title":"J Immunol"},{"issue":"7","key":"3_CR157","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066115","volume":"8","author":"M Parra","year":"2013","unstructured":"Parra M, Liu X, Derrick SC, Yang A, Tian J, Kolibab K, et al. Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination. PLoS One. 2013;8(7):e66115.","journal-title":"PLoS One"},{"issue":"7\u20138","key":"3_CR158","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0264-410X(00)00257-7","volume":"19","author":"S Matsumoto","year":"2000","unstructured":"Matsumoto S, Yukitake H, Kanbara H, Yamada H, Kitamura A, Yamada T. Mycobacterium bovis Bacillus Calmette-Guerin induces protective immunity against infection by Plasmodium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducing protective IgG2a after the parasite infection. Vaccine. 2000;19(7\u20138):779\u201387.","journal-title":"Vaccine"},{"issue":"12","key":"3_CR159","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.cmi.2019.06.002","volume":"25","author":"JC Dos Santos","year":"2019","unstructured":"Dos Santos JC, Vilela Teodoro Silva M, Ribeiro-Dias F, Joosten LAB. Non-specific effects of BCG in protozoal infections: tegumentary leishmaniasis and malaria. Clin Microbiol Infect. 2019;25(12):1479\u201383.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"3_CR160","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1128\/iai.16.1.249-257.1977","volume":"16","author":"LL Smrkovski","year":"1977","unstructured":"Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB\/c mice. Infect Immun. 1977;16(1):249\u201357.","journal-title":"Infect Immun"},{"issue":"3","key":"3_CR161","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4269\/ajtmh.2009.81.378","volume":"81","author":"LI Pereira","year":"2009","unstructured":"Pereira LI, Dorta ML, Pereira AJ, Bastos RP, Oliveira MA, Pinto SA, et al. Increase of NK cells and proinflammatory monocytes are associated with the clinical improvement of diffuse cutaneous leishmaniasis after immunochemotherapy with BCG\/Leishmania antigens. Am J Trop Med Hyg. 2009;81(3):378\u201383.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"3_CR162","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/infdis\/160.1.104","volume":"160","author":"J Convit","year":"1989","unstructured":"Convit J, Castellanos PL, Ulrich M, Castes M, Rondon A, Pinardi ME, et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis. 1989;160(1):104\u201315.","journal-title":"J Infect Dis"},{"issue":"1","key":"3_CR163","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1590\/S0074-02762004000100010","volume":"99","author":"J Convit","year":"2004","unstructured":"Convit J, Ulrich M, Polegre MA, Avila A, Rodriguez N, Mazzedo MI, et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerin: preliminary report. Mem Inst Oswaldo Cruz. 2004;99(1):57\u201362.","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"3_CR164","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1590\/S0037-86822006000100003","volume":"39","author":"W Mayrink","year":"2006","unstructured":"Mayrink W, Botelho AC, Magalhaes PA, Batista SM, Lima Ade O, Genaro O, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop. 2006;39(1):14\u201321.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3\u20134","key":"3_CR165","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0264-410X(02)00458-9","volume":"21","author":"MH Alimohammadian","year":"2002","unstructured":"Alimohammadian MH, Khamesipour A, Darabi H, Firooz A, Malekzadeh S, Bahonar A, et al. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine. 2002;21(3\u20134):174\u201380.","journal-title":"Vaccine"},{"issue":"2","key":"3_CR166","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1046\/j.1365-2249.2003.02299.x","volume":"134","author":"M Mahmoodi","year":"2003","unstructured":"Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, Emamjomeh M, et al. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clin Exp Immunol. 2003;134(2):303\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"3_CR167","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3181\/00379727-152-39327","volume":"152","author":"SE Starr","year":"1976","unstructured":"Starr SE, Visintine AM, Tomeh MO, Nahmias AJ. Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc Soc Exp Biol Med. 1976;152(1):57\u201360.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"2","key":"3_CR168","first-page":"173","volume":"127","author":"F Floc'h","year":"1976","unstructured":"Floc'h F, Werner GH. Increased resistance to virus infections of mice inoculated with BCG (Bacillus Calmette-Guerin). Ann Immunol (Paris). 1976;127(2):173\u201386.","journal-title":"Ann Immunol (Paris)"},{"issue":"2","key":"3_CR169","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/infdis\/136.2.171","volume":"136","author":"JC Spencer","year":"1977","unstructured":"Spencer JC, Ganguly R, Waldman RH. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. J Infect Dis. 1977;136(2):171\u20135.","journal-title":"J Infect Dis"},{"issue":"7","key":"3_CR170","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180143","volume":"12","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee S, Subramaniam R, Chen H, Smith A, Keshava S, Shams H. Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia. PLoS One. 2017;12(7):e0180143.","journal-title":"PLoS One"},{"issue":"3","key":"3_CR171","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41590-023-01739-z","volume":"25","author":"KA Tran","year":"2024","unstructured":"Tran KA, Pernet E, Sadeghi M, Downey J, Chronopoulos J, Lapshina E, et al. BCG immunization induces CX3CR1(hi) effector memory T cells to provide cross-protection via IFN-gamma-mediated trained immunity. Nat Immunol. 2024;25(3):418\u201331.","journal-title":"Nat Immunol"},{"key":"3_CR172","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fimmu.2018.00029","volume":"9","author":"A Scheid","year":"2018","unstructured":"Scheid A, Borriello F, Pietrasanta C, Christou H, Diray-Arce J, Pettengill MA, et al. Adjuvant effect of Bacille Calmette-Guerin on Hepatitis B vaccine immunogenicity in the preterm and term newborn. Front Immunol. 2018;9:29.","journal-title":"Front Immunol"},{"issue":"5\u20136","key":"3_CR173","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000452171","volume":"23","author":"S Kulkarni","year":"2016","unstructured":"Kulkarni S, Mukherjee S, Pandey A, Dahake R, Padmanabhan U, Chowdhary AS. Bacillus Calmette-Guerin confers neuroprotection in a murine model of Japanese encephalitis. Neuroimmunomodulation. 2016;23(5\u20136):278\u201386.","journal-title":"Neuroimmunomodulation"},{"issue":"1","key":"3_CR174","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1128\/iai.19.1.225-230.1978","volume":"19","author":"DL Lodmell","year":"1978","unstructured":"Lodmell DL, Ewalt LC. Enhanced resistance against encephalomyocarditis virus infection in mice, induced by a nonviable Mycobacterium tuberculosis oil-droplet vaccine. Infect Immun. 1978;19(1):225\u201330.","journal-title":"Infect Immun"},{"issue":"3","key":"3_CR175","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1128\/iai.22.3.740-745.1978","volume":"22","author":"DL Lodmell","year":"1978","unstructured":"Lodmell DL, Ewalt LC. Induction of enhanced resistance against encephalomyocarditis virus infection of mice by nonviable Mycobacterium tuberculosis: mechanisms of protection. Infect Immun. 1978;22(3):740\u20135.","journal-title":"Infect Immun"},{"issue":"1","key":"3_CR176","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1128\/iai.20.1.312-314.1978","volume":"20","author":"T Suenaga","year":"1978","unstructured":"Suenaga T, Okuyama T, Yoshida I, Azuma M. Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance. Infect Immun. 1978;20(1):312\u20134.","journal-title":"Infect Immun"},{"issue":"2","key":"3_CR177","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1128\/iai.42.2.567-573.1983","volume":"42","author":"T Sakuma","year":"1983","unstructured":"Sakuma T, Suenaga T, Yoshida I, Azuma M. Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect Immun. 1983;42(2):567\u201373.","journal-title":"Infect Immun"},{"issue":"4","key":"3_CR178","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0166-3542(85)90025-7","volume":"5","author":"S Ikeda","year":"1985","unstructured":"Ikeda S, Negishi T, Nishimura C. Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs. Antivir Res. 1985;5(4):207\u201315.","journal-title":"Antivir Res"},{"issue":"8","key":"3_CR179","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1128\/JVI.02393-08","volume":"83","author":"KS Mathurin","year":"2009","unstructured":"Mathurin KS, Martens GW, Kornfeld H, Welsh RM. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. J Virol. 2009;83(8):3528\u201339.","journal-title":"J Virol"},{"issue":"23","key":"3_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126203","volume":"42","author":"MA Ramirez","year":"2024","unstructured":"Ramirez MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, Ramirez E, Gonzalez PA, et al. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity. Vaccine. 2024;42(23):126203.","journal-title":"Vaccine"},{"issue":"1","key":"3_CR181","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.1038\/s41467-023-43447-0","volume":"14","author":"KL Hilligan","year":"2023","unstructured":"Hilligan KL, Namasivayam S, Clancy CS, Baker PJ, Old SI, Peluf V, et al. Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2. Nat Commun. 2023;14(1):8229.","journal-title":"Nat Commun"},{"key":"3_CR182","doi-asserted-by":"publisher","first-page":"1232764","DOI":"10.3389\/fimmu.2023.1232764","volume":"14","author":"KL Hilligan","year":"2023","unstructured":"Hilligan KL, Namasivayam S, Sher A. BCG mediated protection of the lung against experimental SARS-CoV-2 infection. Front Immunol. 2023;14:1232764.","journal-title":"Front Immunol"},{"issue":"11","key":"3_CR183","doi-asserted-by":"publisher","first-page":"e157393","DOI":"10.1172\/jci.insight.157393","volume":"7","author":"BZ Zhang","year":"2022","unstructured":"Zhang BZ, Shuai H, Gong HR, Hu JC, Yan B, Yuen TT, et al. Bacillus Calmette-Guerin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight. 2022;7(11):e157393.","journal-title":"JCI Insight"},{"issue":"2","key":"3_CR184","doi-asserted-by":"publisher","first-page":"e20211862","DOI":"10.1084\/jem.20211862","volume":"219","author":"KL Hilligan","year":"2022","unstructured":"Hilligan KL, Namasivayam S, Clancy CS, O'Mard D, Oland SD, Robertson SJ, et al. Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge. J Exp Med. 2022;219(2):e20211862.","journal-title":"J Exp Med"},{"key":"3_CR185","doi-asserted-by":"publisher","first-page":"1429909","DOI":"10.3389\/fimmu.2024.1429909","volume":"15","author":"TW Ng","year":"2024","unstructured":"Ng TW, Furuyama W, Wirchnianski AS, Saavedra-Avila NA, Johndrow CT, Chandran K, et al. A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus. Front Immunol. 2024;15:1429909.","journal-title":"Front Immunol"},{"issue":"32","key":"3_CR186","doi-asserted-by":"publisher","first-page":"eabc1463","DOI":"10.1126\/sciadv.abc1463","volume":"6","author":"MK Berg","year":"2020","unstructured":"Berg MK, Yu Q, Salvador CE, Melani I, Kitayama S. Mandated Bacillus Calmette-Guerin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Sci Adv. 2020;6(32):eabc1463.","journal-title":"Sci Adv"},{"issue":"7","key":"3_CR187","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/all.14345","volume":"75","author":"M Gursel","year":"2020","unstructured":"Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy. 2020;75(7):1815\u20139.","journal-title":"Allergy"},{"key":"3_CR188","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fimmu.2020.00970","volume":"11","author":"C Covian","year":"2020","unstructured":"Covian C, Retamal-Diaz A, Bueno SM, Kalergis AM. Could BCG vaccination induce protective trained immunity for SARS-CoV-2? Front Immunol. 2020;11:970.","journal-title":"Front Immunol"},{"issue":"30","key":"3_CR189","doi-asserted-by":"publisher","first-page":"17720","DOI":"10.1073\/pnas.2008410117","volume":"117","author":"LE Escobar","year":"2020","unstructured":"Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA. 2020;117(30):17720\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"3_CR190","doi-asserted-by":"publisher","first-page":"25203","DOI":"10.1073\/pnas.2016733117","volume":"117","author":"CS Lindestam Arlehamn","year":"2020","unstructured":"Lindestam Arlehamn CS, Sette A, Peters B. Lack of evidence for BCG vaccine protection from severe COVID-19. Proc Natl Acad Sci USA. 2020;117(41):25203\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"3_CR191","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2020.8189","volume":"323","author":"U Hamiel","year":"2020","unstructured":"Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA. 2020;323(22):2340\u20131.","journal-title":"JAMA"},{"issue":"6","key":"3_CR192","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.cmi.2023.01.019","volume":"29","author":"EL Koekenbier","year":"2023","unstructured":"Koekenbier EL, Fohse K, van de Maat JS, Oosterheert JJ, van Nieuwkoop C, Hoogerwerf JJ, et al. Bacillus Calmette-Guerin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. Clin Microbiol Infect. 2023;29(6):781\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"3_CR193","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/cid\/ciac182","volume":"75","author":"S Moorlag","year":"2022","unstructured":"Moorlag S, Taks E, Ten Doesschate T, van der Vaart TW, Janssen AB, Muller L, et al. Efficacy of BCG vaccination against respiratory tract infections in older adults during the coronavirus disease 2019 pandemic. Clin Infect Dis. 2022;75(1):e938\u2013e46.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3_CR194","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-024-00992-z","volume":"24","author":"LF Pittet","year":"2024","unstructured":"Pittet LF, Noble CCA, Messina NL, Curtis N. Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation. Nat Rev Immunol. 2024;24(2):83\u20134.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3_CR195","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1525-1470.2012.01848.x","volume":"30","author":"A Salem","year":"2013","unstructured":"Salem A, Nofal A, Hosny D. Treatment of common and plane warts in children with topical viable Bacillus Calmette-Guerin. Pediatr Dermatol. 2013;30(1):60\u20133.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"3_CR196","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4103\/0378-6323.193623","volume":"83","author":"I Podder","year":"2017","unstructured":"Podder I, Bhattacharya S, Mishra V, Sarkar TK, Chandra S, Sil A, et al. Immunotherapy in viral warts with intradermal Bacillus Calmette-Guerin vaccine versus intradermal tuberculin purified protein derivative: a double-blind, randomized controlled trial comparing effectiveness and safety in a tertiary care center in Eastern India. Indian J Dermatol Venereol Leprol. 2017;83(3):411.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"3_CR197","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4103\/ijd.IJD_558_16","volume":"64","author":"AK Jaisinghani","year":"2019","unstructured":"Jaisinghani AK, Dey VK, Suresh MS, Saxena A. Bacillus Calmette-Guerin immunotherapy for recurrent multiple warts: an open-label uncontrolled study. Indian J Dermatol. 2019;64(2):164.","journal-title":"Indian J Dermatol"},{"issue":"3","key":"3_CR198","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/dth.12336","volume":"29","author":"D Daulatabad","year":"2016","unstructured":"Daulatabad D, Pandhi D, Singal A. BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area? Dermatol Ther. 2016;29(3):168\u201372.","journal-title":"Dermatol Ther"},{"key":"3_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102203","volume":"64","author":"LF Pittet","year":"2023","unstructured":"Pittet LF, Moore CL, McDonald E, Barry S, Bonten M, Campbell J, et al. Bacillus Calmette-Guerin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial. EClinicalMedicine. 2023;64:102203.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"3_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2151","volume":"31","author":"LF Pittet","year":"2021","unstructured":"Pittet LF, Curtis N. Does Bacillus Calmette-Guerin vaccine prevent herpes simplex virus recurrences? A systematic review. Rev Med Virol. 2021;31(1):1\u20139.","journal-title":"Rev Med Virol"},{"issue":"12","key":"3_CR201","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/infdis\/jiv332","volume":"212","author":"J Leentjens","year":"2015","unstructured":"Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van Crevel R, et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis. 2015;212(12):1930\u20138.","journal-title":"J Infect Dis"},{"issue":"30","key":"3_CR202","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1016\/j.vaccine.2013.03.059","volume":"31","author":"N Ritz","year":"2013","unstructured":"Ritz N, Mui M, Balloch A, Curtis N. Non-specific effect of Bacille Calmette-Guerin vaccine on the immune response to routine immunisations. Vaccine. 2013;31(30):3098\u2013103.","journal-title":"Vaccine"},{"issue":"2","key":"3_CR203","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4049\/jimmunol.168.2.919","volume":"168","author":"MO Ota","year":"2002","unstructured":"Ota MO, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, et al. Influence of Mycobacterium bovis Bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol. 2002;168(2):919\u201325.","journal-title":"J Immunol"},{"issue":"8","key":"3_CR204","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1080\/21645515.2019.1706930","volume":"16","author":"MA Yamazaki-Nakashimada","year":"2020","unstructured":"Yamazaki-Nakashimada MA, Unzueta A, Berenise Gamez-Gonzalez L, Gonzalez-Saldana N, Sorensen RU. BCG: a vaccine with multiple faces. Hum Vaccin Immunother. 2020;16(8):1841\u201350.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"3_CR205","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224433","volume":"14","author":"ON Gofrit","year":"2019","unstructured":"Gofrit ON, Klein BY, Cohen IR, Ben-Hur T, Greenblatt CL, Bercovier H. Bacillus Calmette-Guerin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients. PLoS One. 2019;14(11):e0224433.","journal-title":"PLoS One"},{"issue":"6","key":"3_CR206","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/j.clgc.2021.05.001","volume":"19","author":"JI Kim","year":"2021","unstructured":"Kim JI, Zhu D, Barry E, Kovac E, Aboumohamed A, Agalliu I, et al. Intravesical Bacillus Calmette-Guerin treatment is inversely associated with the risk of developing Alzheimer disease or other dementia among patients with non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2021;19(6):e409\u2013e16.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"3_CR207","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/vaccines9050491","volume":"9","author":"D Klinger","year":"2021","unstructured":"Klinger D, Hill BL, Barda N, Halperin E, Gofrit ON, Greenblatt CL, et al. Bladder cancer immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer\u2019s disease and Parkinson\u2019s disease. Vaccines (Basel). 2021;9(5):491.","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"3_CR208","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/WAD.0000000000000530","volume":"36","author":"D Makrakis","year":"2022","unstructured":"Makrakis D, Holt SK, Bernick C, Grivas P, Gore JL, Wright JL. Intravesical BCG and incidence of Alzheimer disease in patients with bladder cancer: results from an administrative dataset. Alzheimer Dis Assoc Disord. 2022;36(4):307\u201311.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"3_CR209","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14336","volume":"6","author":"MS Weinberg","year":"2023","unstructured":"Weinberg MS, Zafar A, Magdamo C, Chung SY, Chou WH, Nayan M, et al. Association of BCG vaccine treatment with death and dementia in patients with non-muscle-invasive bladder cancer. JAMA Netw Open. 2023;6(5):e2314336.","journal-title":"JAMA Netw Open"},{"key":"3_CR210","doi-asserted-by":"publisher","first-page":"1243588","DOI":"10.3389\/fnagi.2023.1243588","volume":"15","author":"C Han","year":"2023","unstructured":"Han C, Wang J, Chen YL, Guan CP, Zhang YA, Wang MS. The role of Bacillus Calmette-Guerin administration on the risk of dementia in bladder cancer patients: a systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1243588.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"3_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27425","volume":"10","author":"TP Umar","year":"2024","unstructured":"Umar TP, Jain N, Stevanny B, Javed B, Priandhana A, Siburian R, et al. Protective role of Bacillus Calmette-Guerin vaccine in Alzheimer's disease progression: a systematic review and meta-analysis. Heliyon. 2024;10(5):e27425.","journal-title":"Heliyon"},{"key":"3_CR212","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.nbd.2017.02.001","volume":"101","author":"Z Zuo","year":"2017","unstructured":"Zuo Z, Qi F, Yang J, Wang X, Wu Y, Wen Y, et al. Immunization with Bacillus Calmette-Guerin (BCG) alleviates neuroinflammation and cognitive deficits in APP\/PS1 mice via the recruitment of inflammation-resolving monocytes to the brain. Neurobiol Dis. 2017;101:27\u201339.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"3_CR213","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016610","volume":"6","author":"J Yong","year":"2011","unstructured":"Yong J, Lacan G, Dang H, Hsieh T, Middleton B, Wasserfall C, et al. BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease. PLoS One. 2011;6(1):e16610.","journal-title":"PLoS One"},{"issue":"10","key":"3_CR214","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/jnr.23253","volume":"91","author":"G Lacan","year":"2013","unstructured":"Lacan G, Dang H, Middleton B, Horwitz MA, Tian J, Melega WP, et al. Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci Res. 2013;91(10):1292\u2013302.","journal-title":"J Neurosci Res"},{"issue":"3","key":"3_CR215","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/fcp.12968","volume":"38","author":"NG Yedke","year":"2024","unstructured":"Yedke NG, Soni D, Kumar P. Effect of Bacille-Calmette-Guerin vaccine against rotenone-induced Parkinson's disease: role of neuroinflammation and neurotransmitters. Fundam Clin Pharmacol. 2024;38(3):538\u201349.","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"3_CR216","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/ije\/dyac039","volume":"51","author":"O Nakken","year":"2022","unstructured":"Nakken O, Holmoy T, Stigum H, Myhr KM, Dahl J, Heldal E, et al. Strong tuberculin response after BCG vaccination is associated with low multiple sclerosis risk: a population-based cohort study. Int J Epidemiol. 2022;51(5):1637\u201344.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"3_CR217","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/WNL.53.7.1588","volume":"53","author":"G Ristori","year":"1999","unstructured":"Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, et al. Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis. Neurology. 1999;53(7):1588\u20139.","journal-title":"Neurology"},{"issue":"2","key":"3_CR218","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00415-003-0967-6","volume":"250","author":"A Paolillo","year":"2003","unstructured":"Paolillo A, Buzzi MG, Giugni E, Sabatini U, Bastianello S, Pozzilli C, et al. The effect of Bacille Calmette-Guerin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. J Neurol. 2003;250(2):247\u20138.","journal-title":"J Neurol"},{"issue":"1","key":"3_CR219","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1212\/01.wnl.0000438216.93319.ab","volume":"82","author":"G Ristori","year":"2014","unstructured":"Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology. 2014;82(1):41\u20138.","journal-title":"Neurology"},{"key":"3_CR220","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3389\/fimmu.2018.02777","volume":"9","author":"C Lippens","year":"2018","unstructured":"Lippens C, Garnier L, Guyonvarc'h PM, Santiago-Raber ML, Hugues S. Extended freeze-dried BCG instructed pDCs induce suppressive tregs and dampen EAE. Front Immunol. 2018;9:2777.","journal-title":"Front Immunol"},{"issue":"9","key":"3_CR221","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.4049\/jimmunol.181.9.6201","volume":"181","author":"J Lee","year":"2008","unstructured":"Lee J, Reinke EK, Zozulya AL, Sandor M, Fabry Z. Mycobacterium bovis bacille Calmette-Guerin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner. J Immunol. 2008;181(9):6201\u201312.","journal-title":"J Immunol"},{"issue":"1","key":"3_CR222","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0021-9150(98)00284-6","volume":"143","author":"DJ Lamb","year":"1999","unstructured":"Lamb DJ, Eales LJ, Ferns GA. Immunization with Bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis. 1999;143(1):105\u201313.","journal-title":"Atherosclerosis"},{"issue":"1","key":"3_CR223","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/joim.12127","volume":"275","author":"OA Ovchinnikova","year":"2014","unstructured":"Ovchinnikova OA, Berge N, Kang C, Urien C, Ketelhuth DF, Pottier J, et al. Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis. J Intern Med. 2014;275(1):49\u201358.","journal-title":"J Intern Med"},{"issue":"10","key":"3_CR224","first-page":"1511","volume":"11","author":"S Bekkering","year":"2022","unstructured":"Bekkering S, Singh K, Lu H, Limawan AP, Nold-Petry CA, Wallace MJ, et al. Neonatal subcutaneous BCG vaccination decreases atherosclerotic plaque number and plaque macrophage content in ApoE(\u2212\/\u2212) mice. Biology (Basel). 2022;11(10):1511.","journal-title":"Biology (Basel)"},{"key":"3_CR225","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.atherosclerosis.2016.05.031","volume":"251","author":"AD van Dam","year":"2016","unstructured":"van Dam AD, Bekkering S, Crasborn M, van Beek L, van den Berg SM, Vrieling F, et al. BCG lowers plasma cholesterol levels and delays atherosclerotic lesion progression in mice. Atherosclerosis. 2016;251:6\u201314.","journal-title":"Atherosclerosis"},{"key":"3_CR226","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607957","volume":"11","author":"MA Huaman","year":"2020","unstructured":"Huaman MA, Qualls JE, Jose S, Schmidt SM, Moussa A, Kuhel DG, et al. Mycobacterium bovis Bacille-Calmette-Guerin infection aggravates atherosclerosis. Front Immunol. 2020;11:607957.","journal-title":"Front Immunol"},{"issue":"50","key":"3_CR227","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1016\/j.vaccine.2021.07.092","volume":"39","author":"M Kowalewicz-Kulbat","year":"2021","unstructured":"Kowalewicz-Kulbat M, Locht C. BCG for the prevention and treatment of allergic asthma. Vaccine. 2021;39(50):7341\u201352.","journal-title":"Vaccine"},{"issue":"1","key":"3_CR228","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jaci.2010.07.039","volume":"127","author":"DL Arnoldussen","year":"2011","unstructured":"Arnoldussen DL, Linehan M, Sheikh A. BCG vaccination and allergy: a systematic review and meta-analysis. J Allergy Clin Immunol. 2011;127(1):246\u201353, 53 e1\u201321.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3_CR229","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ije\/dyp307","volume":"39","author":"M El-Zein","year":"2010","unstructured":"El-Zein M, Parent ME, Benedetti A, Rousseau MC. Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies. Int J Epidemiol. 2010;39(2):469\u201386.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"3_CR230","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jaci.2013.08.007","volume":"133","author":"MF Linehan","year":"2014","unstructured":"Linehan MF, Nurmatov U, Frank TL, Niven RM, Baxter DN, Sheikh A. Does BCG vaccination protect against childhood asthma? Final results from the Manchester Community Asthma Study retrospective cohort study and updated systematic review and meta-analysis. J Allergy Clin Immunol. 2014;133(3):688\u201395 e14.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3_CR231","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S1081-1206(10)61890-X","volume":"88","author":"IS Choi","year":"2002","unstructured":"Choi IS, Koh YI. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2002;88(6):584\u201391.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"3_CR232","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1034\/j.1398-9995.2003.00246.x","volume":"58","author":"IS Choi","year":"2003","unstructured":"Choi IS, Koh YI. Effects of BCG revaccination on asthma. Allergy. 2003;58(11):1114\u20136.","journal-title":"Allergy"},{"issue":"4","key":"3_CR233","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/WOX.0b013e31816c8b85","volume":"1","author":"EA Datau","year":"2008","unstructured":"Datau EA, Mewengkang H, Matheos JC, Purnawan I, Wibisono M, Wongdjaja K, et al. Clinical efficacy and laboratory improvement of Bacillus Calmette-Guerin vaccination on adult atopic asthma: a cohort study. World Allergy Organ J. 2008;1(4):63\u20139.","journal-title":"World Allergy Organ J"},{"issue":"5","key":"3_CR234","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1398-9995.2008.01637.x","volume":"63","author":"H Shen","year":"2008","unstructured":"Shen H, Huang H, Wang J, Ye S, Li W, Wang K, et al. Neonatal vaccination with Bacillus Calmette-Guerin elicits long-term protection in mouse-allergic responses. Allergy. 2008;63(5):555\u201363.","journal-title":"Allergy"},{"issue":"2","key":"3_CR235","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1203\/01.pdr.0000196368.08210.5c","volume":"59","author":"R Li","year":"2006","unstructured":"Li R, Yang X, Wang L, Liu E. Respiratory syncytial virus infection reversed anti-asthma effect of neonatal Bacillus Calmette-Guerin vaccination in BALB\/c mice. Pediatr Res. 2006;59(2):210\u20135.","journal-title":"Pediatr Res"},{"issue":"3","key":"3_CR236","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10875-010-9503-5","volume":"31","author":"Y Deng","year":"2011","unstructured":"Deng Y, Chen W, Zang N, Li S, Luo Y, Ni K, et al. The antiasthma effect of neonatal BCG vaccination does not depend on the Th17\/Th1 but IL-17\/IFN-gamma balance in a BALB\/c mouse asthma model. J Clin Immunol. 2011;31(3):419\u201329.","journal-title":"J Clin Immunol"},{"issue":"18","key":"3_CR237","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.vaccine.2014.02.007","volume":"32","author":"Y Deng","year":"2014","unstructured":"Deng Y, Li W, Luo Y, Wang LJ, Xie XH, Luo J, et al. Inhibition of IFN-gamma promotes anti-asthma effect of Mycobacterium bovis Bacillus Calmette-Guerin neonatal vaccination: a murine asthma model. Vaccine. 2014;32(18):2070\u20138.","journal-title":"Vaccine"},{"issue":"3","key":"3_CR238","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1046\/j.0019-2805.2002.01377.x","volume":"105","author":"X Yang","year":"2002","unstructured":"Yang X, Fan Y, Wang S, Han X, Yang J, Bilenki L, et al. Mycobacterial infection inhibits established allergic inflammatory responses via alteration of cytokine production and vascular cell adhesion molecule-1 expression. Immunology. 2002;105(3):336\u201343.","journal-title":"Immunology"},{"issue":"1","key":"3_CR239","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10875-012-9746-4","volume":"33","author":"AC Gouveia","year":"2013","unstructured":"Gouveia AC, Brugiolo AS, Alves CC, Silva FM, Mesquita FP, Gameiro J, et al. Th2 responses in OVA-sensitized BALB\/c mice are down-modulated by Mycobacterium bovis BCG treatment. J Clin Immunol. 2013;33(1):235\u201345.","journal-title":"J Clin Immunol"},{"key":"3_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103186","volume":"64","author":"R Tarancon","year":"2021","unstructured":"Tarancon R, Mata E, Uranga S, Gomez AB, Marinova D, Otal I, et al. Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment. EBioMedicine. 2021;64:103186.","journal-title":"EBioMedicine"},{"issue":"1","key":"3_CR241","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/0008-8749(91)90139-3","volume":"138","author":"H Yagi","year":"1991","unstructured":"Yagi H, Matsumoto M, Kishimoto Y, Makino S, Harada M. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice. Cell Immunol. 1991;138(1):142\u20139.","journal-title":"Cell Immunol"},{"issue":"2","key":"3_CR242","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0168-8227(90)90017-N","volume":"8","author":"M Harada","year":"1990","unstructured":"Harada M, Kishimoto Y, Makino S. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res Clin Pract. 1990;8(2):85\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"3_CR243","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2337\/diab.39.5.583","volume":"39","author":"MW Sadelain","year":"1990","unstructured":"Sadelain MW, Qin HY, Lauzon J, Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes. 1990;39(5):583\u20139.","journal-title":"Diabetes"},{"issue":"8","key":"3_CR244","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/00007890-199404270-00013","volume":"57","author":"JR Lakey","year":"1994","unstructured":"Lakey JR, Singh B, Warnock GL, Rajotte RV. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice. Transplantation. 1994;57(8):1213\u20137.","journal-title":"Transplantation"},{"issue":"8899","key":"3_CR245","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0140-6736(94)91583-0","volume":"343","author":"N Shehadeh","year":"1994","unstructured":"Shehadeh N, Calcinaro F, Bradley BJ, Bruchim I, Vardi P, Lafferty KJ. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet. 1994;343(8899):706\u20137.","journal-title":"Lancet"},{"key":"3_CR246","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1749-6632.2002.tb02990.x","volume":"958","author":"CB Sanjeevi","year":"2002","unstructured":"Sanjeevi CB, Das AK, Shtauvere-Brameus A. BCG vaccination and GAD65 and IA-2 autoantibodies in autoimmune diabetes in southern India. Ann N Y Acad Sci. 2002;958:293\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"3_CR247","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.2337\/diacare.28.5.1204","volume":"28","author":"M Huppmann","year":"2005","unstructured":"Huppmann M, Baumgarten A, Ziegler AG, Bonifacio E. Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care. 2005;28(5):1204\u20136.","journal-title":"Diabetes Care"},{"issue":"10","key":"3_CR248","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2337\/diacare.22.10.1703","volume":"22","author":"HF Allen","year":"1999","unstructured":"Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care. 1999;22(10):1703\u20137.","journal-title":"Diabetes Care"},{"issue":"9064","key":"3_CR249","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/S0140-6736(05)62100-9","volume":"349","author":"P Pozzilli","year":"1997","unstructured":"Pozzilli P. BCG vaccine in insulin-dependent diabetes mellitus. IMDIAB Group. Lancet. 1997;349(9064):1520\u20131.","journal-title":"Lancet"},{"issue":"6","key":"3_CR250","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/joim.13050","volume":"288","author":"DL Faustman","year":"2020","unstructured":"Faustman DL. Benefits of BCG-induced metabolic switch from oxidative phosphorylation to aerobic glycolysis in autoimmune and nervous system diseases. J Intern Med. 2020;288(6):641\u201350.","journal-title":"J Intern Med"},{"key":"3_CR251","doi-asserted-by":"crossref","unstructured":"Faustman DL. TNF, TNF inducers, and TNFR2 agonists: a new path to type 1 diabetes treatment. Diabetes Metab Res Rev. 2018;34(1).","DOI":"10.1002\/dmrr.2941"},{"issue":"8","key":"3_CR252","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041756","volume":"7","author":"DL Faustman","year":"2012","unstructured":"Faustman DL, Wang L, Okubo Y, Burger D, Ban L, Man G, et al. Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One. 2012;7(8):e41756.","journal-title":"PLoS One"},{"issue":"2","key":"3_CR253","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tem.2018.11.006","volume":"30","author":"WM Kuhtreiber","year":"2019","unstructured":"Kuhtreiber WM, Faustman DL. BCG therapy for type 1 diabetes: restoration of balanced immunity and metabolism. Trends Endocrinol Metab. 2019;30(2):80\u201392.","journal-title":"Trends Endocrinol Metab"},{"key":"3_CR254","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41541-018-0062-8","volume":"3","author":"WM Kuhtreiber","year":"2018","unstructured":"Kuhtreiber WM, Tran L, Kim T, Dybala M, Nguyen B, Plager S, et al. Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. NPJ Vaccines. 2018;3:23.","journal-title":"NPJ Vaccines"},{"issue":"12","key":"3_CR255","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.tem.2018.10.001","volume":"29","author":"R Stienstra","year":"2018","unstructured":"Stienstra R, Netea MG. Firing up glycolysis: BCG vaccination effects on type 1 diabetes mellitus. Trends Endocrinol Metab. 2018;29(12):813\u20134.","journal-title":"Trends Endocrinol Metab"},{"key":"3_CR256","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2049-3002-2-12","volume":"2","author":"S Andrzejewski","year":"2014","unstructured":"Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014;2:12.","journal-title":"Cancer Metab"},{"issue":"1","key":"3_CR257","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41541-020-0169-6","volume":"5","author":"CA Segura-Cerda","year":"2020","unstructured":"Segura-Cerda CA, Marquina-Castillo B, Lozano-Ordaz V, Mata-Espinosa D, Barrios-Payan JA, Lopez-Torres MO, et al. BCG and BCGDeltaBCG1419c protect type 2 diabetic mice against tuberculosis via different participation of T and B lymphocytes, dendritic cells and pro-inflammatory cytokines. NPJ Vaccines. 2020;5(1):21.","journal-title":"NPJ Vaccines"},{"issue":"5","key":"3_CR258","doi-asserted-by":"publisher","first-page":"e133788","DOI":"10.1172\/jci.insight.133788","volume":"5","author":"RK Radhakrishnan","year":"2020","unstructured":"Radhakrishnan RK, Thandi RS, Tripathi D, Paidipally P, McAllister MK, Mulik S, et al. BCG vaccination reduces the mortality of Mycobacterium tuberculosis-infected type 2 diabetes mellitus mice. JCI Insight. 2020;5(5):e133788.","journal-title":"JCI Insight"},{"key":"3_CR259","first-page":"657","volume":"23","author":"T Kawasaki","year":"1970","unstructured":"Kawasaki T. Two cases with acute febrile mucocutaneous lymph node syndrome possibly induced by vaccinia or measles vaccination. Jpn J Pediatr. 1970;23:657\u201362.","journal-title":"Jpn J Pediatr"},{"issue":"2","key":"3_CR260","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0190-9622(97)80376-3","volume":"37","author":"S Kuniyuki","year":"1997","unstructured":"Kuniyuki S, Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol. 1997;37(2):303\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"3_CR261","doi-asserted-by":"publisher","DOI":"10.1590\/1984-0462\/2021\/39\/2019338","volume":"39","author":"LMO Diniz","year":"2021","unstructured":"Diniz LMO, Castanheira RG, Giampietro YG, Silva MS, Nogueira FD, Pessoa PD, et al. Diagnostic value of the reaction at the Bacillus Calmette-Guerin vaccination site in Kawasaki disease. Rev Paul Pediatr. 2021;39:e2019338.","journal-title":"Rev Paul Pediatr"},{"key":"3_CR262","doi-asserted-by":"publisher","first-page":"bcr2015213875","DOI":"10.1136\/bcr-2015-213875","volume":"2016","author":"C Novais","year":"2016","unstructured":"Novais C, Fortunato F, Bicho A, Preto L. Bacillus Calmette-Guerin reactivation as a sign of incomplete Kawasaki disease. BMJ Case Rep. 2016;2016:bcr2015213875.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"3_CR263","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1348-0421.2011.00393.x","volume":"56","author":"M Fujieda","year":"2012","unstructured":"Fujieda M, Karasawa R, Takasugi H, Yamamoto M, Kataoka K, Yudoh K, et al. A novel anti-peroxiredoxin autoantibody in patients with Kawasaki disease. Microbiol Immunol. 2012;56(1):56\u201361.","journal-title":"Microbiol Immunol"},{"issue":"7","key":"3_CR264","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/BF03401796","volume":"6","author":"G Sireci","year":"2000","unstructured":"Sireci G, Dieli F, Salerno A. T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease. Mol Med. 2000;6(7):581\u201390.","journal-title":"Mol Med"},{"issue":"2","key":"3_CR265","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S0022-3476(06)80113-7","volume":"122","author":"N Sato","year":"1993","unstructured":"Sato N, Sagawa K, Sasaguri Y, Inoue O, Kato H. Immunopathology and cytokine detection in the skin lesions of patients with Kawasaki disease. J Pediatr. 1993;122(2):198\u2013203.","journal-title":"J Pediatr"},{"issue":"5","key":"3_CR266","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/INF.0b013e3181cacede","volume":"29","author":"R Uehara","year":"2010","unstructured":"Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guerin inoculation site. Pediatr Infect Dis J. 2010;29(5):430\u20133.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"3_CR267","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1097\/INF.0000000000001633","volume":"36","author":"LM Garrido-Garcia","year":"2017","unstructured":"Garrido-Garcia LM, Castillo-Moguel A, Vazquez-Rivera M, Cravioto P, Fernando G. Reaction of the BCG scar in the acute phase of Kawasaki disease in Mexican children. Pediatr Infect Dis J. 2017;36(10):e237\u2013e41.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"3_CR268","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12887-019-1635-z","volume":"19","author":"S Muthuvelu","year":"2019","unstructured":"Muthuvelu S, Lim KS, Huang LY, Chin ST, Mohan A. Measles infection causing Bacillus Calmette-Guerin reactivation: a case report. BMC Pediatr. 2019;19(1):251.","journal-title":"BMC Pediatr"},{"issue":"4","key":"3_CR269","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1620\/tjem.228.351","volume":"228","author":"Y Kakisaka","year":"2012","unstructured":"Kakisaka Y, Ohara T, Katayama S, Suzuki T, Sasai S, Hino-Fukuyo N, et al. Human herpes virus type 6 can cause skin lesions at the BCG inoculation site similar to Kawasaki disease. Tohoku J Exp Med. 2012;228(4):351\u20133.","journal-title":"Tohoku J Exp Med"}],"container-title":["Tuberculosis Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-94540-3_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T01:03:20Z","timestamp":1758675800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-94540-3_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031945397","9783031945403"],"references-count":269,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-94540-3_3","relation":{},"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"31 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}